

DNA Damage Response Inhibitors (DDRi)

Phase 1 study: M9466 + carboplatin—solid tumors; M9466 + carboplatin + etoposide + atezolizumab—SCLC




Merck KGaA, Darmstadt, Germany entered into a collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd., China, including an exclusive license worldwide (ex-China) to develop, manufacture and commercialize M9466. Within China, M9466 is known as HRS-1167. M9466 is investigational and not approved for any use. The safety and efficacy of M9466 in advanced solid tumors has not been established. There is no guarantee M9466 will be approved in the sought-after indication by any health authority worldwide.

Sponsor: Affiliates of Merck KGaA, Darmstadt, Germany

NCT06719973 [Not yet recruiting]

DDRiver 521: Phase 1, open-label, multicenter study



^aPatients who have exhausted all standard of care options according to international guidelines; ^bPatients who have no history of systemic treatment for the disease and must be considered suitable to receive carboplatin, etoposide, and atezolizumab as first-line treatment for extensive stage-SCLC; ^cPer RECIST version 1.1 (as assessed by investigator). DLT, dose-limiting toxicity; DoR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; Est., estimated; LA/M, locally advanced or metastatic; OR, objective response; PFS, progression-free survival; PK, pharmacokinetic; RECIST, Response Evaluation Criteria in Solid Tumors; SCLC, small-cell lung cancer; TEAEs, treatment-emergent adverse events; USA, United States of America. This information is current as of March 2025. ©2025 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada. This material is intended for healthcare professionals only.



For more information on this clinical trial, scan the QR code.

